BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2015 4:41:00 PM | Browse: 857 | Download: 986
 |
Received |
|
2015-06-24 08:39 |
|
Peer-Review Started |
|
2015-06-24 14:32 |
|
To Make the First Decision |
|
2015-07-28 10:50 |
|
Return for Revision |
|
2015-08-05 16:25 |
|
Revised |
|
2015-09-01 21:37 |
|
Second Decision |
|
2015-09-29 17:22 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2015-10-13 18:07 |
|
Articles in Press |
|
2015-10-13 18:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-11-05 18:13 |
|
Publish the Manuscript Online |
|
2015-11-27 16:41 |
| ISSN |
2219-2824 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Chimeric antigen receptors: On the road to realising their full potential
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
May CI van Schalkwyk and John Maher |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wellcome Trust |
|
| June Hancock Mesothelioma Foundation |
|
| Jon Moulton Charitable Foundation |
|
| Pancreatic Cancer United Kingdom, the Experimental Cancer Medicine Centre at King’s College London |
|
| Cancer Research UK, Bayer, the Medical Research Council, Breast Cancer Now, Leukaemia and Lymphoma Research, Worldwide Cancer Research, |
|
| National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust |
|
| King’s College London |
|
|
| Corresponding Author |
Dr. John Maher, CAR Mechanics Group, Department of Research Oncology, Guy’s Hospital Campus, King’s Health Partners Integrated Cancer Centre, King’s College London, Third floor Bermondsey Wing, Great Maze Pond, London SE1 9RT, United Kingdom. john.maher@kcl.ac.uk |
| Key Words |
Adoptive T-cell immunotherapy; Chimeric antigen receptor; Genetic engineering; Leukaemia; Cancer |
| Core Tip |
Adoptive immunotherapy using chimeric antigen receptor-engineered T-cells has been in development for 25 years and, recently, has achieved striking impact in the management of B-cell malignancies. However, the therapy is often accompanied by significant toxicity, in particular cytokine release syndrome. While efficacy in B-cell acute leukaemia provides important clinical proof of concept, this therapy remains unproven in the arena of solid tumours and other disease types. Furthermore, manufacture of cell products is complex and difficult to scale out for widespread clinical use. Significant effort on all of these fronts will be required to enable this promising immunotherapy to enter the therapeutic mainstream. |
| Publish Date |
2015-11-27 16:41 |
| Citation |
van Schalkwyk MCI, Maher J. Chimeric antigen receptors: On the road to realising their full potential. World J Immunol 2015; 5(3): 86-94 |
| URL |
http://www.wjgnet.com/2219-2824/full/v5/i3/86.htm |
| DOI |
http://dx.doi.org/10.5411/wji.v5.i3.86 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
